Results 171 to 180 of about 49,324 (252)

Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B. [PDF]

Clin Pharmacokinet
Wojciechowski J, Gaitonde P, Hughes JH, Ravva P.   +3 more
europepmc   +1 more source

Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9 [PDF]

, 2019
Curiel, David T, Kashentseva, Elena, Lauron, Elvin J, Lu, Zhi Hong, Stephens, Calvin J, Yokoyama, Wayne M   +5 more
core   +1 more source

Radionuclides in the postoperative management of orthotopic human organ transplantation. [PDF]

, 1969
Brown, DW, Starzl, TE
core   +1 more source

Use of Recombinant Factor IX and Thromboelastography in a Patient With Hemophilia B Undergoing Liver Transplantation: A Case Report

, 2008
Lesley De Pietri, Michele Masetti, Roberto Montalti, B. Begliomini, A Reggiani, Elisa Barbieri, Emanuela Biagioni, Marco Marietta, Antonio Romano, Alberto Pasetto, Giorgio Enrico Gerunda   +10 more
openalex   +2 more sources

Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies. [PDF]

Blood Adv
Pipe S, Poma A, Rajasekhar A, Everington T, Sankoh S, Allen J, Cataldo J, Crombez E.   +7 more
europepmc   +1 more source

Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes [PDF]

, 2014
Allen, G, Li, L, Mahlangu, JN, Pasi, J, Pierce, GF, Quon, DV, Shapiro, AD, Zhu, Y   +7 more
core  

The human genes for hemophilia A and hemophilia B flank the X chromosome fragile site at Xq27.3. [PDF]

, 1985
Michele Purrello, Becky Alhadeff, Diane Esposito, Piroska E. Szabó, Mariano Rocchi, Martha Truett, Frank R. Masiarz, M. Siniscalco   +7 more
openalex   +1 more source

Extravascular factor IX after gene therapy in hemophilia B, does it matter? [PDF]

Res Pract Thromb Haemost
Van Thillo Q, Hermans C.
europepmc   +1 more source

Current status of treatment and disease burden of a cohort of hemophilia B in China. [PDF]

Front Public Health, 2023
Huang Y, Wan C, Guan T, Xi X.
europepmc   +1 more source

Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. [PDF]

Blood Adv
von Drygalski A, Gomez E, Giermasz A, Castaman G, Key NS, Lattimore SU, Leebeek FWG, Miesbach WA, Recht M, Monahan PE, Le Quellec S, Pipe SW.   +11 more
europepmc   +1 more source